Clinical trials: H1N1/Influenza Infection
Autoimmune Diseases
Vaccination Against Influenza in Autoimmune Diseases
The project is to evaluate immunogenicity, efficacy and tolerance of vaccination against influenza (seasonal and H1N1) in patients affected with systemic and autoimmune diseases.
- Trial name
- MAIVAX (NCT01065285)
- Testing
- Evaluation of vaccines against flu
- Where
- France
- Volunteers
- 234 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Influenza
Safety Study of Live Attenuated Influenza Vaccine, CodaVax, Delivered Via Intranasal Spray
This study is being conducted to assess the safety, tolerability, and immunogenicity of the live-attenuated CodaVax-H1N1 influenza vaccine as compared to normal saline placebo both administered via intranasal spray to healthy…
- Trial name
- NCT04146623
- Testing
- CodaVax-H1N1 influenza vaccine
- Where
- Australia
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Codagenix, Inc
Influenza
The Long-term Immunogenicity of an Inactivated Split-virion 2009 Pandemic Influenza A H1N1 Vaccine
The aim of this study is to investigate the long-term immunogenicity and safety of the inactivated split-virion vaccine after one immunization.
- Trial name
- NCT01336166
- Testing
- split-virion, non-adjuvanted H1N1 vaccine of 15 μg, split-virion, non-adjuvanted H1N1 vaccine of 30 μg, split-virion, non-adjuvanted H1N1 vaccine of 45 μg
- Where
- China
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza A Virus Infection, Swine Flu
A Pilot Study for Collection of Anti-Influenza A Immune Plasma
Background: The influenza A virus can cause infections that lead to fever, cough, muscle aches, diarrhea, and headaches, and can even be fatal in some people.
- Trial name
- NCT00984451
- Testing
- Plasma collection following infection or vaccination with influenza A
- Where
- 12 sites in United States
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Rheumatic Diseases
Vaccination Against Influenza H1N1 in Rheumatic Diseases
The spread of Influenza H1N1 has prompted the development of vaccines against this virus. Immunocompromised patients are at increased risk of developing complications of Influenza H1N1.
- Trial name
- NCT01006681
- Testing
- Focetria (Monovalent MF59-Adjuvanted vaccine)
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
A/H1N1 Influenza, Swine Flu
Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon
The pandemic A/H1N1 virus was named "swine flu" when the current outbreak started. Although it is not yet confirmed that the index case acquired the virus from pigs, the nomenclature "swine flu" was due to the fact that the virus…
- Trial name
- NCT01298206
- Where
- Lebanon
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Influenza
Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children
The objective of this study is to evaluate the safety and immunogenicity study of GSK Biologicals' pandemic influenza candidate vaccine (GSK2340272A) in children aged 3 to 9 years.
- Trial name
- NCT01014091
- Testing
- GSK pandemic vaccine GSK2340272A
- Where
- 3 sites in Czechia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A, Influenza B
Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza
This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B.
- Trial name
- IRC002 (NCT01052480)
- Testing
- Anti-Influenza Immune Plasma, Standard Care
- Where
- 35 sites in United States
- Volunteers
- 98 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults
This study is designed to characterize the safety and immunogenicity of a' pandemic influenza (H1N1) candidate vaccine GSK2340274A in adults 19 to 40 years who have never received influenza vaccination.
- Trial name
- NCT01059617
- Testing
- GSK Biologicals' FluLaval®, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A
- Where
- 3 sites in United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
H1N1 Influenza, Seasonal Influenza
Characteristics and Outcomes of Intensive Care Unit Patients Admitted With Novel H1N1 Influenza or Seasonal Influenza
The purpose of this research study is to collect information on problems that patients with the novel H1N1 influenza and/or the seasonal influenza experience. Novel H1N1 flu is also called the swine flu.
- Trial name
- NCT01011582
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Virginia Commonwealth University
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The purpose of the study is to evaluate the safety and immunogenicity of GSK Biologicals' influenza vaccine GSK2340272A.
- Trial name
- NCT00951041
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- 3 sites in Germany
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Evaluating the Use of Oseltamivir for the Treatment of Influenza in Adults
People who are infected with the influenza virus may develop respiratory illnesses, such as pneumonia, or other life-threatening complications. Currently, there are four antiviral medications that are used to treat influenza.
- Trial name
- NCT01314911
- Testing
- Oseltamivir
- Where
- 51 sites in United States, Argentina and 1 more
- Volunteers
- 716 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A H1N1
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
A total of up to 90 participants may be given H1N1 influenza challenge virus. In Part A, 40 participants will be randomly allocated to one of two groups to be given one of two virus doses (Virus Dose 1 or Virus Dose 2).
- Trial name
- NCT05572450
- Testing
- Infectious Titre 1, Infectious Titre 2, Infectious Titre 3
- Where
- United Kingdom
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Hvivo
Influenza
Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine
This study will evaluate the immunological response and the safety profiles of seasonal, inactivated vaccine which contains in its composition the A/California/7/2009 H1N1 "pandemic" influenza virus, delivered via ID in reduced…
- Trial name
- NCT01582633
- Testing
- 2012 trivalent influenza vaccine
- Where
- Brazil
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo General Hospital
2009 H1N1 Influenza Virus
Effects of Age on Response to the 2009 H1N1 Virus Vaccine
Unlike most influenza viruses, the 2009 H1N1 virus has affected people between 5 and 40 years old more often than people 60 years old or older.
- Trial name
- NCT01055184
- Testing
- 2009 H1N1 Virus Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Influenza
A Study of Tamiflu (Oseltamivir) for Treatment of Influenza With a Focus on (H1N1) 2009 Flu Strain
This randomized, double-blind, multi-center study of Tamiflu (Oseltamivir) will evaluate the efficacy against viral activity, the effectiveness in resolving the disease symptoms, and the safety and tolerability in patients with…
- Trial name
- NCT01032837
- Testing
- Oseltamivir
- Where
- 100 sites in United States
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche
Influenza
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
The objective of the study is to evaluate the immunogenicity and safety of GSK Biologicals' investigational vaccine GSK2340272A.
- Trial name
- NCT00968539
- Testing
- GSK investigational vaccine GSK2340272A, GSK investigational vaccine GSK2340269A
- Where
- Belgium
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Efficacy Study of Interferon to Treat Patients Hospitalized for Influenza
A Pilot Study to Evaluate the Safety and Efficacy of interferon-Alfacon1 (INFERGEN) in the treatment of patients hospitalized with Influenza-like illness caused by a novel swine origin Influenza virus and other circulating…
- Trial name
- NCT01227798
- Testing
- Interferon alfacon-1
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Influenza
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes
The objective of this study is to evaluate the immunogenicity and safety of one or two doses of GSK Biologicals' investigational influenza vaccine GSK2340272A, manufactured using two different processes, in adults aged 18 to 60…
- Trial name
- NCT00992511
- Testing
- GSK investigational vaccine GSK2340272A
- Where
- 4 sites in Germany
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunologic Response to Inactivated Vaccine for Novel H1N1 Virus
The purpose of this study is to describe the immune response to a novel H1N1 influenza vaccination in healthy adults, and to understand the factors that allow healthy adults to respond to a single dose of vaccine even if they…
- Trial name
- NCT01023711
- Testing
- Inactivated H1N1 vaccine
- Where
- United States
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Rochester